The aforementioned ARV-110, also known as bavdegalutamide, induced potent AR degradation in prostate cancer cell lines with a DC50 of ~1 nM and reduced prostate-specific antigen (PSA) levels greater than or equal to 50% (PSA50) in 46% of metastatic castration-resistant prostate cancer (mCRPC) patients with tumors harboring AR T878X and/or H875Y (X = A or S) mutations in its Phase I/II clinical trial [9,18]. This evidence concerns the gene KLK3 and prostate carcinoma.